MIRAGEN THERAPEUTICS, INC. Form SC 13D/A March 07, 2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

SCHEDULE 13D/A (Amendment No. 1)

Under the Securities Exchange Act of 1934

Miragen Therapeutics, Inc. (Name of Issuer)

Miragen Therapeutics, Inc. (Title of Class of Securities)

60463E103 (CUSIP Number)

Kyle A. Lefkoff 1941 Pearl Street, Suite 300 Boulder, Colorado 80302 303) 444-6950 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

February 13, 2017

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rules 13d 1(e), 13d-1(f) or 13d-1(g), check the following box. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No.	60463E103 13D/APage 2 of 13 Pages Name of Reporting Person/ I.R.S. Identification No. of Above Person (Entities Only)					
1	Boulder Ventures V, L.P. 01-0893942 Check the Appropriate Box if a Member of a Group					
2	(a) (b)					
3	SEC USE ONLY					
4	Source of Funds (See Instructions) OO					
5	Check if Disclosure of Legal Proceedings is Required Pursuant to 2(d) or 2(e)	Items				
6	Citizenship or Place of Organization					
	Delaware					
Number of Shares	7 Sole Voting Power	1,607,437				
Beneficially Owned by Each	Shared Voting Power	0				
	9 Sole Dispositive Power	1,607,437				
reison wit	10 Shared Dispositive Power	0				
11	Aggregate Amount Beneficially Owned by Each Reporting Perso 1,607,437	n				
12	Check if the Aggregate Amount in Row (11) Excludes Certain Sh (See Instructions)	nares				
13	Percent of Class Represented by Amount in Row (11)	7.5%*				
14	Type of Reporting Person	PN				
* The deno	minator is based on the approximately 21.3 million shares of the co	ommon stock reported by the				

^{*} The denominator is based on the approximately 21.3 million shares of the common stock reported by the Issuer to be issued and outstanding as of February 13, 2017, in its Current Report on Form 8-K, as filed with the Securities and Exchange Commission on February 13, 2017.

CUSIP No. 60463E103 13D/A Page 3 of 13 Pages

1	I.F Pe B	ame of Reporting Person/ R.S. Identification No. of A erson (Entities Only) V Partners V, L.L.C. -00893943	above	
2	Check the Appropriate Box if a Member of a Group (a) (b)			
3	SE	EC Use Only		
4	Sc	ource of Funds (See Instruc O	ctions)	
5	Pr	neck if Disclosure of Legal roceedings is Required Purseums 2(d) or 2(e)		
6		tizenship or Place of Orga	nization	
	7	Sole Voting Power	1,607,437	
Shares Beneficially Owned by	8	Shared Voting Power	0	
		Sole Dispositive Power	1,607,437	
Person With		Shared Dispositive Power	0	
11	Aggregate Amount Beneficially Owned by Each Reporting Person 1,607,437			
12	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)			
13	Percent of Class Represented 7.5%* by Amount in Row (11)			
14	Ту	pe of Reporting Person	OO	

^{*} The denominator is based on the approximately 21.3 million shares of the common stock reported by the Issuer to be issued and outstanding as of February 13, 2017, in its Current Report on Form 8-K, as filed with the Securities and Exchange Commission on February 13, 2017.

CUSIP No. 60463E103 13D/A Page 4 of 13 Pages

1	Name of Reporting Person/ I.R.S. Identification No. of Above Person (Entities Only) Boulder Ventures VI, L.P. 46-3860105			
2			f a	
3	SE	EC Use Only		
4	So O(ource of Funds (See Instruc	tions)	
5	Pr	neck if Disclosure of Legal oceedings is Required Purs ems 2(d) or 2(e)	suant to	
6	Or	tizenship or Place of ganization		
Number of	7	Sole Voting Power	474,273	
Shares Beneficially Owned by	8	Shared Voting Power	0	
Each Reporting Person With		Sole Dispositive Power	474,273	
i cison win		Shared Dispositive Power	0	
11	Aggregate Amount Beneficially Owned by Each Reporting Person 474,273			
12	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)			
13	by	ercent of Class Represented Amount in Row 1)2.4%*	2.2%*	

14 Type of Reporting Person PN

^{*} The denominator is based on the approximately 21.3 million shares of the common stock reported by the Issuer to be issued and outstanding as of February 13, 2017, in its Current Report on Form 8-K, as filed with the Securities and Exchange Commission on February 13, 2017.

CUSIP No. 60463E103 13D/A Page 5 of 13 Pages

1	Name of Reporting Person/ I.R.S. Identification No. of Above Person (Entities Only) BV Partners VI, L.L.C. 46-3847523				
2	Check the Appropriate Box if a Member of a Group (a) (b)				
3	SEC Use Only				
4	Source of Funds (See Instructions) OO				
5	Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)				
6	Citizenship or Place of Organization				
	De	elaware			
Number of Shares	7	Sole Voting Power	474,273		
Beneficially Owned by Each	8	Shared Voting Power	0		
		Sole Dispositive Power	474,273		
reison win		Shared Dispositive Power	0		
11	Aggregate Amount Beneficially Owned by Each Reporting Person 474,273				
12	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)				
13	Percent of Class Represented by Amount in Row (11) 2.2%*				
14	Ту	pe of Reporting Person	OO		

^{*} The denominator is based on the approximately 21.3 million shares of the common stock reported by the Issuer to be issued and outstanding as of February 13, 2017, in its Current Report on Form 8-K, as filed with the Securities and Exchange Commission on February 13, 2017.

CUSIP No. 60463E103 13D/A Page 6 of 13 Pages

Name of

Reporting

Person/

I.R.S.

Identification

No. of Above

Person

(Entities

Only)

Kyle Lefkoff

